Evidence map›Paper›PMID 42251428›Full record

ArticleAIDS research and therapy2026

Kidney abnormalities in young people living with HIV on dolutegravir-based regimens in Kampala, Uganda.

Esther M Nasuuna, Risa Hoffman, Robert Kalyesubula, Chido Dziva Chikwari, Helen A Weiss

Abstract read
In one paragraph

Article in AIDS research and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Esther M NasuunaNon-communicable Diseases Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda. enasuuna@idi.co.ug.
Risa HoffmanDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Robert KalyesubulaNon-communicable Diseases Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Chido Dziva ChikwariBiomedical Research and Training Institute, Harare, Zimbabwe.
Helen A WeissMRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.

Funding

HIV Co-infections in Uganda: TB, Cryptococcus, and Viral Hepatitis.D43TW009771 · FIC · JOHNS HOPKINS UNIVERSITY · PI CASTELNUOVO, BARBARA, KAMBUGU, ANDREW DDUNGU · 2014 to 2023
$3.3M
FIC NIH HHS D43 TW009771FIC NIH HHS grant #2D43TW009771-06
6 · The paper itself

Abstract

We assessed the association between dolutegravir (DTG)-based antiretroviral therapy and kidney abnormalities among young people living with HIV in Kampala, Uganda. Cross-sectional albumin-creatinine ratio (ACR), proteinuria, and estimated glomerular filtration rate (eGFR) were measured. Among 483 participants, the mean serum creatinine was higher (0.68 vs. 0.59) and creatinine-based eGFR lower (118.8 vs. 113.9), among those on TDF/DTG. Cystatin C-based eGFR, prevalences of elevated ACR (9.6% vs. 13.0%), proteinuria (28.3% vs. 30.2%), and eGFR < 90 ml/min/1.73 m² (40.1% vs. 46.9%) were similar. Kidney abnormalities were not associated with regimen, supporting the need for longitudinal studies to clarify progression risk.

Indexed as

Anti-HIV AgentsHeterocyclic Compounds, 3-RingHIV InfectionsHIV Integrase InhibitorsKidney DiseasesAdolescentAdultCreatinineCross-Sectional StudiesDolutegravirFemaleGlomerular Filtration RateHumansMaleOxazinesPiperazinesAnti-HIV AgentsCreatinineDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridonesDolutegravirKidney functionSub Saharan AfricaYoung people living with HIV

Identifiers

PMID42251428
PMCPMC13459296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.